TONIX PHARMACEUTICALS HOLDING CORP (TNXP)
Health Care · Biopharmaceutical development and commercial-stage pharmaceutical company · NASDAQ
A fully-integrated biopharmaceutical company commercializing TONMYA (cyclobenzaprine sublingual tablets) for fibromyalgia while advancing a pipeline of CNS, immunology, and infectious disease therapies.
What TONIX PHARMACEUTICALS HOLDING CORP does
Tonix Pharmaceuticals is a biopharmaceutical company that develops and commercializes innovative therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. The company's lead marketed product is TONMYA (cyclobenzaprine HCl sublingual tablets), approved by the FDA in August 2025 and launched November 2025 for fibromyalgia treatment in adults—the first new medicine for fibromyalgia in over 15 years. Tonix also markets two FDA-approved migraine products: Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray). The company operates a commercial platform with sales, marketing, market access, and patient support capabilities, while advancing a pipeline of development candidates through internal discovery, in-licensing, acquisitions, and strategic collaborations.
Themes: ["Fibromyalgia treatment","Migraine therapeutics","Major depressive disorder / mental health","Acute stress disorder / trauma","CNS / neurology","Rare diseases","Immunology","Infectious diseases"]
Fundamentals
- Price$13.03 as of 2026-07-09 close
- Market cap$204M as of 2026-07-10
- 1-year return-66.0% as of 2026-07-09 close
- Net margin-839.5% as of 2026-07-10
- Gross margin+58.6% as of 2026-07-10
- ROE-67.7% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+74.8% as of 2026-07-10
- Revenue CAGR (3y)+29.9% SEC XBRL
- Beta1.70 as of 2026-07-10
Key risks (from latest filing)
["Early-stage commercialization of TONMYA with significant operating losses (net margin -839.52%) and reliance on cash reserves ($185.5M as of March 2026) to fund operations and R&D.","Highly concentrated revenue from recently launched TONMYA and two migraine products in a competitive market with established therapies; adoption and reimbursement risks for new fibromyalgia indication.","Significant pipeline development risk across CNS, immunology, and infectious disease programs requiring successful clinical trials, regulatory approvals, and commercialization to generate future revenue growth."]
Competitors & peers
- Pfizer (fibromyalgia, migraine)
- Eli Lilly (fibromyalgia)
- Vertex Pharmaceuticals (pain management)
- Biohaven Pharmaceuticals (migraine)
- Allergan/AbbVie (migraine)
- GSK (migraine)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.